Woodline Partners’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.3M Hold
102,469
– – 0.07% 361
2026
Q2
$27.3M Hold
102,469
– – 0.08% 302
2026
Q1
$23.4M Buy
102,469
+8
+0% +$1.79K 0.09% 304
2025
Q4
$21.8M Hold
102,461
– – 0.08% 293
2025
Q3
$20.4M Sell
102,461
-202,993
-66% -$37.9M 0.1% 277
2025
Q2
$52.7M Buy
305,454
+648
+0.2% +$106K 0.28% 87
2025
Q1
$47.5M Sell
304,806
-12,836
-4% -$1.83M 0.31% 94
2024
Q4
$43.7M Buy
317,642
+82,624
+35% +$10.9M 0.3% 97
2024
Q3
$35.1M Buy
235,018
+36,252
+18% +$4.9M 0.3% 109
2024
Q2
$27.1M Buy
198,766
+2,736
+1% +$372K 0.26% 120
2024
Q1
$29.6M Buy
196,030
+179,881
+1,114% +$25.7M 0.27% 115
2023
Q4
$2.03M Buy
+16,149
New +$1.61M 0.02% 377
2023
Q2
– Sell
-304,796
Closed -$32.7M – 635
2023
Q1
$32.7M Buy
304,796
+209,683
+220% +$24M 0.44% 64
2022
Q4
$11.6M Sell
95,113
-116,280
-55% -$13.5M 0.16% 185
2022
Q3
$21.8M Buy
211,393
+105,267
+99% +$10M 0.31% 93
2022
Q2
$9.9M Sell
106,126
-5,886
-5% -$555K 0.15% 179
2022
Q1
$13.1M Sell
112,012
-112,437
-50% -$13M 0.21% 143
2021
Q4
$30.2M Buy
+224,449
New +$33.4M 0.43% 50
2020
Q1
– Sell
-55,284
Closed -$7.69M – 139
2019
Q4
$7.69M Buy
+55,284
New +$6.14M 0.31% 78

Other funds holding ASND

Woodline Partners's ASND Position: Q3 2026 in Review

Woodline Partners held its Ascendis Pharma (ASND) position steady in Q3 2026 at 102,469 shares worth $23.3M. The position accounts for 0.07% of the portfolio, ranked #361.

Woodline Partners first reported a position in ASND in Q4 2019 and has held it in 19 quarters since. The position peaked at $52.7M in Q2 2025. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Woodline Partners held 102,469 shares of Ascendis Pharma worth $23.3M as of Q3 2026.
  • Woodline Partners left its Ascendis Pharma share count unchanged in Q3 2026.
  • Ascendis Pharma made up 0.07% of Woodline Partners's portfolio in Q3 2026, its #361 holding.
  • Woodline Partners first reported a position in Ascendis Pharma in Q4 2019 and has held it in 19 quarters since.
  • Woodline Partners's Ascendis Pharma position peaked at $52.7M in Q2 2025.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.